Department of Otorhinolaryngology, Head and Neck Surgery, The Second Affiliated Hospital of Anhui Medical University, Hefei, China.
Department of ORL-HNS, College of Health Sciences, Addis Ababa University, Addis Ababa, Ethiopia.
Eur Arch Otorhinolaryngol. 2024 Dec;281(12):6339-6352. doi: 10.1007/s00405-024-08864-x. Epub 2024 Jul 31.
To analyze the overall long-term outcome of surgically treated skull base and temporal bone chondrosarcomas.
The medical records of patients with surgically treated skull base and temporal bone chondrosarcomas between 1983 and 2024 were thoroughly evaluated.
Out of a total of over 5000 skull base surgeries performed at our center, only 29 patients had histopathologically confirmed chondrosarcomas of the skull base and temporal bone. The mean of patients age was 45.6, and the male-to-female ratio was 1.9:1. The most common symptoms included hearing loss (58.6%), tinnitus (41.4%), diplopia (31%), dysphonia (24.1%), dysphagia (20.7%), vertigo (10.3%), and dizziness (10.3%). The most frequent locations of lesions among the 29 patients are as follows: petroclival region (34.5%), jugular foramen (27.6%), petrous apex (17.2%), middle ear (13.8%), others (3.4%). TO, IFTA, IFTB, IFTC, POTS, and combined surgical approaches were commonly used. The rate of gross total removal and recurrence was 82.6% and 13.8% respectively. The follow-up duration of 6 patients was more than five years and less than ten years whereas ten patients had more than ten years of follow-up.
Chondrosarcoma of the skull base and temporal bone is a very rare pathology. Due to its multiple potential sites of origin and histological specificity, it presents us with significant challenges. Gross total removal is the primary treatment for chondrosarcoma of the skull base and temporal bone. Personalized decision-making should be considered based on the following aspects: tumor, patient, and surgeon's factors. Postoperative radiation therapy is complementary to surgical treatment in grades II and III lesions to achieve long-term survival.
分析手术治疗颅底和颞骨软骨肉瘤的总体长期预后。
彻底评估了 1983 年至 2024 年间接受手术治疗的颅底和颞骨软骨肉瘤患者的病历。
在我们中心进行的超过 5000 例颅底手术中，只有 29 例患者的颅底和颞骨软骨肉瘤经组织病理学证实。患者的平均年龄为 45.6 岁，男女比例为 1.9:1。最常见的症状包括听力损失（58.6%）、耳鸣（41.4%）、复视（31%）、发音困难（24.1%）、吞咽困难（20.7%）、眩晕（10.3%）和头晕（10.3%）。29 例患者中病变最常见的部位如下：岩斜区（34.5%）、颈静脉孔（27.6%）、岩尖（17.2%）、中耳（13.8%）、其他部位（3.4%）。TO、IFTA、IFTB、IFTC、POTS 和联合手术入路通常用于治疗。大体全切除率和复发率分别为 82.6%和 13.8%。6 例患者的随访时间超过 5 年但少于 10 年，10 例患者的随访时间超过 10 年。
颅底和颞骨软骨肉瘤是一种非常罕见的病理。由于其多个潜在的起源部位和组织学特异性，给我们带来了重大挑战。大体全切除是颅底和颞骨软骨肉瘤的主要治疗方法。应根据肿瘤、患者和外科医生的因素考虑个性化决策。对于 II 级和 III 级病变，术后放疗是手术治疗的补充，以实现长期生存。
